Department of Anesthesiology, Baylor College of Medicine, Houston, Texas, USA.
Curr Opin Anaesthesiol. 2010 Feb;23(1):49-56. doi: 10.1097/ACO.0b013e3283346c51.
Pulmonary hypertension is associated with high perioperative morbidity and mortality. Management of intraoperative pulmonary hypertension, along with frequently associated right heart failure, is extremely challenging. We now review the pathophysiology and clinical management of pulmonary hypertension, and associated right heart failure.
Pulmonary hypertension results from a combination of both environmental and genetic influences. Current treatments include the use of pulmonary vasodilators, optimization of inotropic agents to support cardiac function, maintenance of perfusion to the right ventricle, and correction of any physiologically detrimental conditions (e.g. hypoxemia, hypercarbia, acidosis, hypothermia, hypervolemia, and increased intrathoracic pressure).
Knowledge of pulmonary hypertension pathophysiology and treatment modalities will not only improve intraoperative management but also reduce postoperative morbidity and mortality.
肺动脉高压与围手术期高发病率和高死亡率相关。术中肺动脉高压以及常合并的右心衰竭的管理极具挑战性。我们现在回顾肺动脉高压和相关右心衰竭的病理生理学和临床管理。
肺动脉高压是由环境和遗传因素共同作用的结果。目前的治疗方法包括使用肺动脉扩张剂、优化正性肌力药物以支持心功能、维持右心室灌注以及纠正任何生理有害的情况(如低氧血症、高碳酸血症、酸中毒、低体温、血容量过多和胸腔内压力增加)。
了解肺动脉高压的病理生理学和治疗方法不仅可以改善术中管理,还可以降低术后发病率和死亡率。